{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:25:11Z","timestamp":1769019911090,"version":"3.49.0"},"reference-count":98,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T00:00:00Z","timestamp":1637020800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>The WHO-category Myelodysplastic\/Myeloproliferative neoplasms (MDS\/MPNs) recognizes a unique group of clonal myeloid malignancies exhibiting overlapping features of myelodysplastic as well as myeloproliferative neoplasms. The group consists of chronic myelomonocytic leukemia (CMML), atypical chronic myeloid leukemia, <jats:italic>BCR-ABL1<\/jats:italic>-negative (aCML), juvenile myelomonocytic leukemia (JMML), myelodysplastic\/myeloproliferative neoplasm with ringed sideroblasts and thrombocytosis (MDS\/MPN-RS-T), and myelodysplastic\/myeloproliferative neoplasms, unclassifiable (MDS\/MPN-U). The most frequent entity in this category is CMML, while all other diseases are extremely rare. Thus, only very limited data on the epidemiology of these subgroups exists. An appropriate diagnosis and classification can be challenging since the diagnosis is still largely based on morphologic criteria and myelodysplastic as well as myeloproliferative features can be found in various occurrences. The diseases in this category share several features that are common in this specific WHO-category, but also exhibit specific traits for each disease. This review summarizes published data on epidemiological features and offers a brief overview of the main diagnostic criteria and clinical characteristics of the five MDS\/MPN subgroups.<\/jats:p>","DOI":"10.3389\/fonc.2021.778741","type":"journal-article","created":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T06:57:15Z","timestamp":1637045835000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Hybrid or Mixed Myelodysplastic\/Myeloproliferative Disorders \u2013 Epidemiological Features and Overview"],"prefix":"10.3389","volume":"11","author":[{"given":"Andrea","family":"Kuendgen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annika","family":"Kasprzak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Germing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,11,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 Revision to the World Health Organization Classification of Myeloid Neoplasms and Acute Leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-714030","article-title":"Integrating Clinical Features and Genetic Lesions in the Risk Assessment of Patients With Chronic Myelomonocytic Leukemia","volume":"128","author":"Elena","year":"2016","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e150","DOI":"10.1097\/HS9.000000000000015","article-title":"Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults: Recommendations From the European Hematology Association and the European Leukemianet","volume":"2","author":"Itzykson","year":"2018","journal-title":"Hemasphere"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.1361","article-title":"Next-Generation Sequencing Technology Reveals a Characteristic Pattern of Molecular Mutations in 72.8% of Chronic Myelomonocytic Leukemia by Detecting Frequent Alterations in TET2, CBL, RAS, and RUNX1","volume":"28","author":"Kohlmann","year":"2010","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1053\/j.seminoncol.2011.11.008","article-title":"Integration of Next-Generation Sequencing Into Clinical Practice: Are We There Yet","volume":"39","author":"Kohlmann","year":"2012","journal-title":"Semin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2020000130","article-title":"Genomics of Myelodysplastic Syndrome\/Myeloproliferative Neoplasm Overlap Syndromes","volume":"2020","author":"Patnaik","year":"2020","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-311019","article-title":"Mutational Spectrum Analysis of Chronic Myelomonocytic Leukemia Includes Genes Associated With Epigenetic Regulation: UTX, EZH2, and DNMT3A","volume":"118","author":"Jankowska","year":"2011","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23702","article-title":"Gene Mutations Differently Impact the Prognosis of the Myelodysplastic and Myeloproliferative Classes of Chronic Myelomonocytic Leukemia","volume":"89","author":"Cervera","year":"2014","journal-title":"Am J Hematol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-274704","article-title":"Next-Generation Sequencing of the TET2 Gene in 355 MDS and CMML Patients Reveals Low-Abundance Mutant Clones With Early Origins, But Indicates No Definite Prognostic Value","volume":"116","author":"Smith","year":"2010","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2014.08.014","article-title":"The Detection of SRSF2 Mutations in Routinely Processed Bone Marrow Biopsies is Useful in the Diagnosis of Chronic Myelomonocytic Leukemia","volume":"45","author":"Federmann","year":"2014","journal-title":"Hum Pathol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-560227","article-title":"Driver Somatic Mutations Identify Distinct Disease Entities Within Myeloid Neoplasms With Myelodysplasia","volume":"124","author":"Malcovati","year":"2014","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2018.1.307","article-title":"JMML Genomics and Decisions","volume":"2018","author":"Niemeyer","year":"2018","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24332","article-title":"Predictors of Survival in Refractory Anemia With Ring Sideroblasts and Thrombocytosis (RARS-T) and the Role of Next-Generation Sequencing","volume":"91","author":"Patnaik","year":"2016","journal-title":"Am J Hematol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.119032","article-title":"Refractory Anemia With Ring Sideroblasts and Marked Thrombocytosis Cases Harbor Mutations in SF3B1 or Other Spliceosome Genes Accompanied by JAK2V617F and ASXL1 Mutations","volume":"100","author":"Jeromin","year":"2015","journal-title":"Haematologica"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e497","DOI":"10.1097\/HS9.0000000000000497","article-title":"Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia","volume":"4","author":"Fontana","year":"2020","journal-title":"Hemasphere"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-05-848473","article-title":"Mutational Landscape of Myelodysplastic\/Myeloproliferative Neoplasm-Unclassifiable","volume":"132","author":"Bose","year":"2018","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0574-x","article-title":"Clinicopathologic Characteristics, Prognostication and Treatment Outcomes for Myelodysplastic\/Myeloproliferative Neoplasm, Unclassifiable (MDS\/MPN-U): Mayo Clinic-Moffitt Cancer Center Study of 135 Consecutive Patients","volume":"34","author":"Mangaonkar","year":"2020","journal-title":"Leukemia"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1976.tb03563.x","article-title":"Proposals for the Classification of the Acute Leukaemias. French-American-British (FAB) Co-Operative Group","volume":"33","author":"Bennett","year":"1976","journal-title":"Br J Haematol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1982.tb08475.x","article-title":"Proposals for the Classification of the Myelodysplastic Syndromes","volume":"51","author":"Bennett","year":"1982","journal-title":"Br J Haematol"},{"key":"B20","article-title":"World Health Organization Classification of Tumours","volume-title":"Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues","author":"Jaffe","year":""},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.227686","article-title":"Myeloid Neoplasms With Isolated Del(5q) and JAK2 V617F Mutation: A \u201cGrey Zone\u201d Combination of Myelodysplastic and Myeloproliferative Features","volume":"105","author":"Sangiorgio","year":"2020","journal-title":"Haematologica"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404215","article-title":"The JAK2 V617F Mutation Identifies a Subgroup of MDS Patients With Isolated Deletion 5q and a Proliferative Bone Marrow","volume":"20","author":"Ingram","year":"2006","journal-title":"Leukemia"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01537.x","article-title":"Isolated Isochromosome 17q: A Distinct Type of Mixed Myeloproliferative Disorder\/Myelodysplastic Syndrome With an Aggressive Clinical Course","volume":"106","author":"McClure","year":"1999","journal-title":"Br J Haematol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.7350","article-title":"Myeloid Neoplasms With Isolated Isochromosome 17q Demonstrate a High Frequency of Mutations in SETBP1, SRSF2, ASXL1 and NRAS","volume":"7","author":"Kanagal-Shamanna","year":"2016","journal-title":"Oncotarget"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26537","article-title":"Myeloid Neoplasms With Isolated Isochromosome 17q Represent a Clinicopathologic Entity Associated With Myelodysplastic\/Myeloproliferative Features, a High Risk of Leukemic Transformation, and Wild-Type TP53","volume":"118","author":"Kanagal-Shamanna","year":"2012","journal-title":"Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.27914","article-title":"Prognostic Significance of Isochromosome 17q in Hematologic Malignancies","volume":"12","author":"Koczkodaj","year":"2021","journal-title":"Oncotarget"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.lrr.2018.06.002","article-title":"Clinical Characteristics and Treatment Outcome of Patients With Isochromosome 17q (I17q) Abnormality and Myeloid Neoplasms: A Single Center Experience","volume":"10","author":"Ganguly","year":"2018","journal-title":"Leuk Res Rep"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.1.225.413k24_225_232","article-title":"Isochromosome 17q in Blast Crisis of Chronic Myeloid Leukemia and in Other Hematologic Malignancies is the Result of Clustered Breakpoints in 17p11 and is Not Associated With Coding TP53 Mutations","volume":"94","author":"Fioretos","year":"1999","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1990.tb00401.x","article-title":"Acute Nonlymphocytic Leukemia (ANLL) With Isochromosome I(17q) as the Sole Chromosomal Anomaly: A Distinct Entity","volume":"44","author":"Weh","year":"1990","journal-title":"Eur J Haematol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/0145-2126(93)90080-5","article-title":"Isochromosome 17q as a Sole Anomaly: A Distinct Myelodysplastic Syndrome Entity","volume":"17","author":"Sol\u00e9","year":"1993","journal-title":"Leuk Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13414","article-title":"Trends in Incidence, Primary Treatment and Survival in Chronic Myelomonocytic Leukaemia: A Population-Based Study of 1359 Patients Diagnosed in the Netherlands From 1989 to 2012","volume":"171","author":"Dinmohamed","year":"2015","journal-title":"Br J Haematol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14061","article-title":"Incidence and Patient Survival of Myeloproliferative Neoplasms and Myelodysplastic\/Myeloproliferative Neoplasms in the United States, 2001-12","volume":"174","author":"Srour","year":"2016","journal-title":"Br J Haematol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2019.01.003","article-title":"Trends of Incidence and Survival of Patients With Chronic Myelomonocytic Leukemia Between 1999 and 2014: A Comparison Between Swiss and American Population-Based Cancer Registries","volume":"59","author":"Benzarti","year":"2019","journal-title":"Cancer Epidemiol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1182\/blood-2008-01-134858","article-title":"Epidemiology of Myelodysplastic Syndromes and Chronic Myeloproliferative Disorders in the United States, 2001-2004, Using Data From the NAACCR and SEER Programs","volume":"112","author":"Rollison","year":"2008","journal-title":"Blood"},{"key":"B35","volume-title":"Data From the Duesseldorf MDS Registry as at 2021","author":"Germing","year":"2021"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-013-1712-6","article-title":"The Incidence of Myelodysplastic Syndromes in Western Greece is Increasing","volume":"92","author":"Avgerinou","year":"2013","journal-title":"Ann Hematol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.10.3534","article-title":"Chronic Myelomonocytic Leukemia in Childhood: A Retrospective Analysis of 110 Cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS)","volume":"89","author":"Niemeyer","year":"1997","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04361.x","article-title":"Paediatric Myelodysplastic Syndromes and Juvenile Myelomonocytic Leukaemia in the UK: A Population-Based Study of Incidence and Survival","volume":"121","author":"Passmore","year":"2003","journal-title":"Br J Haematol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.053918","article-title":"Clinical Features and Course of Refractory Anemia With Ring Sideroblasts Associated With Marked Thrombocytosis","volume":"97","author":"Broseus","year":"2012","journal-title":"Haematologica"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.120","article-title":"Age, JAK2(V617F) and SF3B1 Mutations are the Main Predicting Factors for Survival in Refractory Anaemia With Ring Sideroblasts and Marked Thrombocytosis","volume":"27","author":"Bros\u00e9us","year":"2013","journal-title":"Leukemia"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2405054","article-title":"Prognostic Interaction Between Thrombocytosis and JAK2 V617F Mutation in the WHO Subcategories of Myelodysplastic\/Myeloproliferative Disease-Unclassifiable and Refractory Anemia With Ringed Sideroblasts and Marked Thrombocytosis","volume":"22","author":"Atallah","year":"2008","journal-title":"Leukemia"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404316","article-title":"Refractory Anemia With Ringed Sideroblasts Associated With Marked Thrombocytosis Harbors JAK2 Mutation and Shows Overlapping Myeloproliferative and Myelodysplastic Features","volume":"20","author":"Wang","year":"2006","journal-title":"Leukemia"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-02-553800","article-title":"Atypical Chronic Myeloid Leukemia is Clinically Distinct From Unclassifiable Myelodysplastic\/Myeloproliferative Neoplasms","volume":"123","author":"Wang","year":"2014","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3324\/%25x","article-title":"Identification of Risk Factors in Atypical Chronic Myeloid Leukemia","volume":"91","author":"Breccia","year":"2006","journal-title":"Haematologica"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1023\/a:1008393002748","article-title":"Clinical, Hematological and Cytogenetic Characteristics of Atypical Chronic Myeloid Leukemia","volume":"11","author":"Hern\u00e1ndez","year":"2000","journal-title":"Ann Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10832","article-title":"Characteristics and Outcome of Patients With Philadelphia Chromosome Negative, Bcr\/Abl Negative Chronic Myelogenous Leukemia","volume":"95","author":"Onida","year":"2002","journal-title":"Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.5045\/br.2019.54.3.233","article-title":"Characteristics and Survival of Patients With Atypical Chronic Myeloid Leukemia","volume":"54","author":"Kong","year":"2019","journal-title":"Blood Res"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.8","article-title":"Myelodysplastic\/Myeloproliferative Neoplasms, Unclassifiable (MDS\/MPN, U): Natural History and Clinical Outcome by Treatment Strategy","volume":"28","author":"DiNardo","year":"2014","journal-title":"Leukemia"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2007.07.004","article-title":"Clinical and Prognostic Features of Patients With Myelodysplastic\/Myeloproliferative Syndrome Categorized as Unclassified (MDS\/MPD-U) by WHO Classification","volume":"32","author":"Cannella","year":"2008","journal-title":"Leuk Res"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.119","article-title":"The Myelodysplastic\/Myeloproliferative Neoplasms: Myeloproliferative Diseases With Dysplastic Features","volume":"22","author":"Orazi","year":"2008","journal-title":"Leukemia"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2016.0043","article-title":"Clinical Management of Myelodysplastic Syndrome\/Myeloproliferative Neoplasm Overlap Syndromes","volume":"13","author":"Clara","year":"2016","journal-title":"Cancer Biol Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-553X.2010.01251.x","article-title":"Diagnosing Myelodysplastic\/Myeloproliferative Neoplasms: Laboratory Testing Strategies to Exclude Other Disorders","volume":"32","author":"Hall","year":"2010","journal-title":"Int J Lab Hematol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2011.1.264","article-title":"Myelodysplastic\/Myeloproliferative Neoplasms","volume":"2011","author":"Cazzola","year":"2011","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.114660","article-title":"An International Mds\/Mpn Working Group\u2019s Perspective and Recommendations on Molecular Pathogenesis, Diagnosis and Clinical Characterization of Myelodysplastic\/Myeloproliferative Neoplasms","volume":"100","author":"Mughal","year":"2015","journal-title":"Haematologica"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11051","article-title":"Chronic Myelomonocytic Leukemia in the Light of the WHO Proposals","volume":"92","author":"Germing","year":"2007","journal-title":"Haematologica"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-844688","article-title":"Juvenile Myelomonocytic Leukemia: Who\u2019s the Driver at the Wheel","volume":"133","author":"Niemeyer","year":"2019","journal-title":"Blood"},{"key":"B57","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/j.1600-0609.2009.01283.x","article-title":"The Role of Peripheral Blood, Bone Marrow Aspirate and Especially Bone Marrow Trephine Biopsy in Distinguishing Atypical Chronic Myeloid Leukemia From Chronic Granulocytic Leukemia and Chronic Myelomonocytic Leukemia","volume":"83","author":"Xubo","year":"2009","journal-title":"Eur J Haematol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/ajh.25684","article-title":"Chronic Myelomonocytic Leukemia: 2020 Update on Diagnosis, Risk Stratification and Management","volume":"95","author":"Patnaik","year":"2020","journal-title":"Am J Hematol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-08-452938","article-title":"Development and Validation of a Prognostic Scoring System for Patients With Chronic Myelomonocytic Leukemia","volume":"121","author":"Such","year":"2013","journal-title":"Blood"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.88","article-title":"Mayo Prognostic Model for WHO-Defined Chronic Myelomonocytic Leukemia: ASXL1 and Spliceosome Component Mutations and Outcomes","volume":"27","author":"Patnaik","year":"2013","journal-title":"Leukemia"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.3314","article-title":"Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia","volume":"31","author":"Itzykson","year":"2013","journal-title":"J Clin Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-05-1944","article-title":"Hematopoietic Stem Cell Transplantation (HSCT) in Children With Juvenile Myelomonocytic Leukemia (JMML): Results of the EWOG-MDS\/EBMT Trial","volume":"105","author":"Locatelli","year":"2005","journal-title":"Blood"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2011.06.001","article-title":"Incidence and Prevalence of Myelodysplastic Syndromes: Data From the Dusseldorf MDS-Registry","volume":"35","author":"Neukirchen","year":"2011","journal-title":"Leuk Res"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22570","article-title":"Myelodysplastic Syndromes: Incidence and Survival in the United States","volume":"109","author":"Ma","year":"2007","journal-title":"Cancer"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1996.354","article-title":"Epidemiological Characteristics of Myelodysplastic Syndrome in a Well-Defined French Population","volume":"74","author":"Maynadi\u00e9","year":"1996","journal-title":"Br J Cancer"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10767","article-title":"Mutation Allele Burden Remains Unchanged in Chronic Myelomonocytic Leukaemia Responding to Hypomethylating Agents","volume":"7","author":"Merlevede","year":"2016","journal-title":"Nat Commun"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30487","article-title":"Trends in Childhood Leukemia Incidence Over Two Decades From 1992 to 2013","volume":"140","author":"Barrington-Trimis","year":"2017","journal-title":"Int J Cancer"},{"key":"B68","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1111\/bjh.14460","article-title":"Incidence and Outcomes of Paediatric Myelodysplastic Syndrome in the United States","volume":"180","author":"Xavier","year":"2018","journal-title":"Br J Haematol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-022491","article-title":"High Frequency of the JAK2 V617F Mutation in Patients With Thrombocytosis (Platelet Count>600x109\/L) and Ringed Sideroblasts More Than 15% Considered as MDS\/MPD, Unclassifiable","volume":"109","author":"Gattermann","year":"2007","journal-title":"Blood"},{"key":"B70","article-title":"Atypical Chronic Myeloid Leukemias","volume":"45","author":"Oscier","year":"1997","journal-title":"Pathol Biol (Paris)"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-04-1199","article-title":"The World Health Organization (WHO) Classification of the Myeloid Neoplasms","volume":"100","author":"Vardiman","year":"2002","journal-title":"Blood"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61165-9","article-title":"European Leukemianet. Chronic Myeloid Leukaemia","volume":"370","author":"Hehlmann","year":"2007","journal-title":"Lancet"},{"key":"B73","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.beha.2009.07.007","article-title":"Epidemiology of Chronic Myeloid Leukaemia (CML)","volume":"22","author":"Rohrbacher","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.21870","article-title":"Bone Marrow Fibrosis in Chronic Myelomonocytic Leukemia is Associated With Increased Megakaryopoiesis, Splenomegaly and With a Shorter Median Time to Disease Progression","volume":"8","author":"Petrova-Drus","year":"2017","journal-title":"Oncotarget"},{"key":"B75","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1097\/PAS.0000000000001058","article-title":"Chronic Myelomonocytic Leukemia With Fibrosis is a Distinct Disease Subset With Myeloproliferative Features and Frequent JAK2 P.V617F Mutations","volume":"42","author":"Gur","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3289-6","article-title":"Association of Bone Marrow Fibrosis With Inferior Survival Outcomes in Chronic Myelomonocytic Leukemia","volume":"97","author":"Khan","year":"2018","journal-title":"Ann Hematol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e31825dd4de","article-title":"Specific Skin Lesions in Chronic Myelomonocytic Leukemia: A Spectrum of Myelomonocytic and Dendritic Cell Proliferations: A Study of 42 Cases","volume":"36","author":"Vitte","year":"2012","journal-title":"Am J Surg Pathol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0447-3","article-title":"Biology and Prognostic Impact of Clonal Plasmacytoid Dendritic Cells in Chronic Myelomonocytic Leukemia","volume":"33","author":"Lucas","year":"2019","journal-title":"Leukemia"},{"key":"B79","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/bjh.15794","article-title":"Chronic Myelomonocytic Leukaemia Followed by Blastic Plasmacytoid Dendritic Cell Neoplasm","volume":"185","author":"Lebecque","year":"2019","journal-title":"Br J Haematol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1243681","article-title":"Spectrum of Autoimmune Diseases and Systemic Inflammatory Syndromes in Patients With Chronic Myelomonocytic Leukemia","volume":"58","author":"Zahid","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1159\/000365877","article-title":"A Close Association of Autoimmune-Mediated Processes and Autoimmune Disorders With Chronic Myelomonocytic Leukemia: Observation From a Single Institution","volume":"133","author":"Peker","year":"2015","journal-title":"L.Acta Haematol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2016.1143938","article-title":"Chronic Inflammation and Autoimmunity as Risk Factors for the Development of Chronic Myelomonocytic Leukemia","volume":"57","author":"Elb\u00e6k","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3489-0","article-title":"Cardiovascular Disease in Chronic Myelomonocytic Leukemia: Do Monocytosis and Chronic Inflammation Predispose to Accelerated Atherosclerosis","volume":"98","author":"Elb\u00e6k","year":"2019","journal-title":"Ann Hematol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004229","article-title":"Molecular Landscape and Clonal Architecture of Adult Myelodysplastic\/Myeloproliferative Neoplasms","volume":"136","author":"Palomo","year":"2020","journal-title":"Blood"},{"key":"B85","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/ajh.24939","article-title":"Therapy Related-Chronic Myelomonocytic Leukemia (CMML): Molecular, Cytogenetic, and Clinical Distinctions From De Novo CMML","volume":"93","author":"Patnaik","year":"2018","journal-title":"Am J Hematol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.leukres.2017.12.002","article-title":"Myelodysplastic Syndromes Without Peripheral Monocytosis But With Evidence of Marrow Monocytosis Share Clinical and Molecular Characteristics With CMML","volume":"65","author":"Schuler","year":"2018","journal-title":"Leuk Res"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2019.101137","article-title":"Oligo-Monocytic CMML and Other Pre-CMML States: Clinical Impact, Prognostication and Management","volume":"33","author":"Valent","year":"2020","journal-title":"Best Pract Res Clin Haematol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12071891","article-title":"Clinical, Hematologic, Biologic and Molecular Characteristics of Patients With Myeloproliferative Neoplasms and a Chronic Myelomonocytic Leukemia-Like Phenotype","volume":"12","author":"Heibl","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1989.tb07703.x","article-title":"Three Cases of Myelodysplastic-Myeloproliferative Disorder With Abnormal Chromatin Clumping in Granulocytes","volume":"72","author":"Brizard","year":"1989","journal-title":"Br J Haematol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/j.1365-2141.1988.tb02433.x","article-title":"The Syndrome of Abnormal Chromatin Clumping in Leucocytes: A Myelodysplastic Disorder With Proliferative Features","volume":"70","author":"Felman","year":"1988","journal-title":"Br J Haematol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V35.5.637.637","article-title":"Chromatin Clumping in Mature Leukocytes: A Hitherto Unrecognized Abnormality. Abnormal Chromatin Clumping in Leucocytes: A Clue to a New Subtype of Myelodysplastic Syndrome","volume":"35","author":"Gustke","year":"1970","journal-title":"Blood"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1990.tb00459.x","article-title":"Abnormal Chromatin Clumping in Leucocytes: a Clue to a New Subtype of Myelodysplastic Syndrome","volume":"45","author":"Ja\u00e9n","year":"1990","journal-title":"Eur J Haematol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1080\/1042819042000207271","article-title":"Risk Assessment in Chronic Myelomonocytic Leukemia (CMML)","volume":"45","author":"Germing","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2014.09.003","article-title":"Refined Medullary Blast and White Blood Cell Count Based Classification of Chronic Myelomonocytic Leukemias","volume":"38","author":"Schuler","year":"2014","journal-title":"Leuk Res"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-404863","article-title":"SRSF2 Mutations in 275 Cases With Chronic Myelomonocytic Leukemia (CMML)","volume":"120","author":"Meggendorfer","year":"2012","journal-title":"Blood"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401342","article-title":"Myelodysplastic Syndrome, Juvenile Myelomonocytic Leukemia, and Acute Myeloid Leukemia Associated With Complete or Partial Monosomy 7. European Working Group on MDS in Childhood (EWOG-MDS)","volume":"13","author":"Hasle","year":"1999","journal-title":"Leukemia"},{"key":"B97","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/ng.2495","article-title":"Recurrent SETBP1 Mutations in Atypical Chronic Myeloid Leukemia","volume":"45","author":"Piazza","year":"2013","journal-title":"Nat Genet"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-500959","article-title":"The New Genetics of Chronic Neutrophilic Leukemia and Atypical CML: Implications for Diagnosis and Treatment","volume":"122","author":"Gotlib","year":"2013","journal-title":"Blood"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.778741\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T06:57:20Z","timestamp":1637045840000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.778741\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,16]]},"references-count":98,"alternative-id":["10.3389\/fonc.2021.778741"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.778741","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,16]]},"article-number":"778741"}}